Advances in immuno-oncology (I-O) continue to revolutionize how cancer is treated in community settings. As clinicians apply the latest scientific evidence, they must also know how to effectively navigate institutional policies and procedures to ensure that patients are receiving safe and appropriate care. Cancer centers need to know how to optimize their biomarker testing processes so that appropriate tests are ordered in a timely fashion. Cancer centers also need to have processes in place to ensure that patients who are treated with immune checkpoint inhibitors are monitored closely and that all staff are following treatment guidelines when managing immune-mediated adverse reactions.
This online course will allow pathologists, laboratory professionals, and cancer clinicians to experience a virtual cancer committee discussion that explores ways to improve biomarker testing processes and addresses the complex challenges associated with identifying and managing immune-mediated adverse reactions. The course will illustrate how members of the multidisciplinary cancer care team can work together to identify meaningful clinical and programmatic goals as more patients are treated with immunotherapy. The course will also demonstrate how members of the multidisciplinary cancer care team may lead quality improvement efforts to ensure that patients are receiving safe and effective care within their institutions.
Learning Objectives:
- Discuss the current and evolving role of I-O biomarkers such as PD-L1 and TMB
- Explain pathology-driven approaches to optimizing institutional biomarker testing processes
- Determine ways to identify and manage treatment-related toxicities associated with the use of immune checkpoint inhibitors
- Describe how members of the multidisciplinary cancer care team may lead efforts focused around improving care coordination for patients treated with immunotherapy
Faculty:
Joseph Kim, MD, MPH, MBA
President of Q Synthesis LLC
Langhorne, PA
David R. Penberthy, MD, MBA
Medical Director of Radiation Oncology
Southside Regional Medical Center
Petersburg, VA
John Summerville, MD
Laboratory Director
Southside Regional Medical Center
Petersburg, VA
Tracey Tatum, MS, FNP
Director of Oncology Service Line
Southside Regional Medical Center
Petersburg, VA
The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
These activities also meet Continuing Certification (CC) Part II Lifelong Learning and Self-Assessment Module (SAMs CME) requirements.
ASCP designates these enduring material for a maximum of 1.0 CMLE credit. These activities meet CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Funded by an independent educational grants from Bristol-Myers Squibb.